LAVA Therapeutics N.V. (LVTX) Stock Analysis & Investment Frameworks
LAVA Therapeutics N.V. (LVTX) stock analysis on Invetso. Review LAVA Therapeutics N.V.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
LAVA Therapeutics N.V. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: NL
LAVA Therapeutics N.V. Key Financial Metrics
- Market Cap: $45.77M
- Revenue: $11.98M
- ROE: -97.04%
- ROIC: -31.13%
- Dividend Yield: N/A
About LAVA Therapeutics N.V.
LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer. Key compounds in its clinical pipeline include LAVA-051, currently undergoing Phase 1/2a trials for various hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Another front-runner, LAVA-1207, is also in Phase 1/2a clinical studies, targeting metastatic castration-resistant prostate cancer. Furthermore, LAVA Therapeutics is advancing additional Gammabody candidates: LAVA-1223, an investigational treatment for specific solid tumors that targets the epidermal growth factor receptor (EGFR), and preclinical assets LAVA-1266 and LAVA-1278, intended for a range of blood cancers. The company has also forged a research collaboration and licensing partnership with Janssen Biotech, Inc. This alliance focuses on the potential discovery and development of multi-specific antibody therapies aimed at a particular target across diverse therapeutic applications. Established in 2016, LAVA Therapeutics N.V. operates from its headquarters in Utrecht, the Netherlands.
LAVA Therapeutics N.V. Investment Frameworks
Invetso analyzes LAVA Therapeutics N.V. (LVTX) across the following frameworks:
- LAVA Therapeutics N.V. 10Y Growth Potential
- LAVA Therapeutics N.V. Scenario Analysis
- LAVA Therapeutics N.V. Risks & Opportunities
- LAVA Therapeutics N.V. Economic Moat
- LAVA Therapeutics N.V. Business Model
- LAVA Therapeutics N.V. Management
- LAVA Therapeutics N.V. SWOT Analysis
- LAVA Therapeutics N.V. Porter's 5 Forces
- LAVA Therapeutics N.V. PESTLE Analysis
- LAVA Therapeutics N.V. ESG Analysis